Navigation Links
Abbott's XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
Date:10/13/2008

I and SPIRIT III trials demonstrated the following key results for XIENCE V at two years:

-- A clinically significant 31 percent reduction in the risk of ischemia-driven Target Vessel Failure (TVF, cardiac events related to the treated vessel) compared to TAXUS (10.4 percent for XIENCE V vs. 14.7 percent for TAXUS, p-value=0.03)*. TVF is a composite clinical measure of safety and efficacy outcomes defined as cardiac death, heart attack (myocardial infarction or MI) or target vessel revascularization (TVR).

-- A clinically significant 45 percent reduction in the risk of ischemia-driven major adverse cardiac events (MACE) compared to TAXUS (7.1 percent for XIENCE V vs. 12.3 percent for TAXUS, p-value=0.001). MACE is an important composite clinical measure of safety and efficacy outcomes for patients, defined as cardiac death, heart attack (myocardial infarction or MI), or ischemia-driven target lesion revascularization (TLR driven by lack of blood supply).

-- An observed 28 percent reduction in the risk of all-cause death compared to TAXUS (2.4 percent for XIENCE V vs. 3.3 percent for TAXUS, p-value=0.36)*.

-- An observed 28 percent reduction in the risk of cardiac death compared to TAXUS (0.9 percent for XIENCE V vs. 1.3 percent for TAXUS, p-value=0.56)*.

-- A clinically significant 45 percent reduction in the risk of heart attack (MI) compared to TAXUS (3.1 percent for XIENCE V vs. 5.6 percent for TAXUS, p-value=0.03)*.

-- A clinically significant 39 percent reduction in the risk of all-cause death or heart attack (MI) compared to TAXUS (5.1 percent for XIENCE V vs. 8.3 percent for TAXUS, p-value=0.03)*.

-- A clinically significant 41 percent reduction in the risk of cardiac death or heart attack (MI) compared to TAXUS (3.8 percent for XIENCE V vs. 6.3 percent for TAXUS, p-value=0.04)*.

-- A clinically significant 41 percent reduction in the risk of ischemia-driven target lesion revascularization (ID-TLR) compa
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
2. SPIRIT II Explores Long-Term Performance of XIENCE V Stent
3. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
4. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
5. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
6. Dynavaxs HEPLISAV(TM) Hepatitis B Vaccine Maintains Full Immunogenicity at 50 Weeks in Phase 3 Trial
7. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
8. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
9. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
10. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
11. Largest Study to Date Shows Significant Reductions in Risks of Blood Clots and Reintervention With CYPHER(R) Sirolimus-eluting Coronary Stent Compared to Taxus Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... AUGUSTA, Ga. , March 27, 2015  Holographic ... innovator in the field of holographic medical imaging, is ... of its Kickstarter campaign. Launching on April 20 th ... Voxbox and Voxbox Pro. The 8-inch and 22-inch displays ... at home for the first time. In addition to ...
(Date:3/27/2015)... , March 27, 2015   Cypher Genomics, ... announced new data showing that, compared to a ... technology provided highly equivalent interpretations of whether certain ... did so in a fraction of the time. ... for more comprehensive genetic analysis in non-invasive prenatal ...
(Date:3/27/2015)... , March 27, 2015 XRpro Sciences, ... drug discovery and development services which features high ... pharmaceutical industry, announced financial results for the year ... C.  Tyson, Chairman of XRpro Sciences commented, "We ... transition from development stage to commercial stage in ...
Breaking Medicine Technology:Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 2New Data at ACMG Shows Cypher's Software Can Automate Interpretation of Genetic Variants to Advance Non-invasive Prenatal Testing 3XRpro Sciences Announces Fiscal 2014 Financial Results 2XRpro Sciences Announces Fiscal 2014 Financial Results 3XRpro Sciences Announces Fiscal 2014 Financial Results 4
... AUSTIN, Texas, April 27, 2011 Hanger Orthopedic Group, Inc. ... million for the quarter ended March 31, 2011, an increase ... first quarter of 2010.  Adjusted diluted earnings per share, which ... $0.19 for the first quarter of 2011, an 18.8% increase ...
... N.Y. and BERLIN, April 27, 2011 Regeneron ... today announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic ... macular edema due to central retinal vein occlusion (CRVO).  The ... the similarly designed Phase 3 COPERNICUS study that were announced ...
Cached Medicine Technology:Hanger Orthopedic Group Reports First Quarter Results 2Hanger Orthopedic Group Reports First Quarter Results 3Hanger Orthopedic Group Reports First Quarter Results 4Hanger Orthopedic Group Reports First Quarter Results 5Hanger Orthopedic Group Reports First Quarter Results 6Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion 2Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion 3Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion 4Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion 5Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion 6Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion 7
(Date:3/29/2015)... Chicago, IL (PRWEB) March 29, 2015 ... Foundation for Women’s Cancer announce today that ... 2015 recipient of the Claudia Cohen Research Foundation Prize ... presented at the Society of Gynecologic Oncology 46th Annual ... is Director of the Cedars-Sinai Women’s Cancer Program at ...
(Date:3/29/2015)... 29, 2015 The federal court ... ) pending in the U.S. District Court, Northern ... Case Management Conference for April 21st at 1:30 ... address the progress of product liability claims filed ... attacks, strokes and other cardiovascular complications due to ...
(Date:3/29/2015)... March 29, 2015 Youth Villages will ... in Oregon to assess the feasibility of implementing a ... and behavioral problems and their families. , Third Sector ... participants that will be provided technical assistance throughout 2015 ... join six other national awardees chosen by Third Sector. ...
(Date:3/29/2015)... North American Seminars receives Texas Board Physical Therapy ... . , Utilizing Pilates to Enhance Rehab ... # 56399TX      , The Interactive Shoulder Algorithm ... 10.5 hours - Texas Board of Physical Therapy      ... the SI Joint - 10 hours - Texas Board ...
(Date:3/28/2015)... Rocket Pure , a manufacturer of natural ... their new natural sunscreen. They are offering the sunscreen ... options come with a bonus lip balm sunscreen. , The ... Click to see the natural sunscreen on Amazon ... is made with non-nano zinc oxide and provides broad-based protection ...
Breaking Medicine News(10 mins):Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 2Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 3Health News:Dr. Beth Y. Karlan Named Recipient of the Claudia Cohen Research Foundation Prize for Outstanding Gynecologic Cancer Researcher 2015 4Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 2Health News:Federal Court Overseeing Testosterone Treatment Lawsuits Schedules April Case Management Conference 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 2Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 3Health News:Youth Villages Partners with Two Oregon Counties to Advance Pay-for-Success Model to Help At-Risk Youth 4Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 2Health News:Rocket Pure Releases New Natural Sunscreens For Athletes 3
... Maintains its Top Spot, and Big Pharma Dominates Top ... Thomson,Scientific, part of The Thomson Corporation (NYSE: TOC ... the worldwide research and,business communities, today announced the availability ... Splash?" In this quarterly review of the scientific ...
... populations are an increasing issue for the Western world. The ... has been a rise in older men and women living ... relatives. A new study, funded by the Economic and Social ... a spouse or with others on the health and happiness ...
... favourable clinical outcome in women with ovarian carcinoma, and ... published this week in the online open access journal, ... of peptide hormones, and the receptor GPR54 have previously ... In this study, researchers have shown that kisspeptin and ...
... announced strong sales and earnings for its first,quarter ended September ... per diluted share, on revenues of $2,751,000. This compares to ... revenues of $2,424,000,for the first quarter of last year. ... 13.5% revenue growth, year over year -- Gross margin ...
... N.J., Nov. 14 Roche announced today,that ... has approved MIRCERA,(methoxy polyethylene glycol-epoetin beta) for ... failure (CRF) in adults, including patients,on dialysis ... commonly known as chronic,kidney disease (CKD). MIRCERA ...
... 14 The vast,majority of people required to ... law have failed to do so, according,to an ... Consumer Rights,(FTCR)., A California proposal modeled on ... correct for the affordability crisis faced by,Massachusetts residents. ...
Cached Medicine News:Health News:Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - a Quarterly Review of Scientific Literature on Drugs and Therapies From July - September 2007 2Health News:Thomson Scientific Publishes 'Who Is Making The Biggest Splash?' - a Quarterly Review of Scientific Literature on Drugs and Therapies From July - September 2007 3Health News:Living arrangements, health and well-being: A European perspective 2Health News:Predicting the future in ovarian cancer 2Health News:Biotel Announces Strong Results for the First Quarter Ended September 30, 2007, FDA 510(k) Clearance for the Braemar ER900 Wireless Event Recorder 2Health News:FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing 2Health News:FDA Approves MIRCERA(R): First Renal Anemia Treatment with Monthly Maintenance Dosing 3Health News:Consumer Group to Nunez: Massachusetts Mandatory Health Insurance Purchase Law Is No Model for California 2Health News:Consumer Group to Nunez: Massachusetts Mandatory Health Insurance Purchase Law Is No Model for California 3Health News:Consumer Group to Nunez: Massachusetts Mandatory Health Insurance Purchase Law Is No Model for California 4
... When someone suffers an episode of ... right away. The QuikDraw PRO quickly restores ... immediate pain relief.,With just a few sizes ... clothing sizes, the QuikDraw PRO will reduce ...
Shoulder Immobilizer with Body Strap Navy blue cotton. Thumb look helps keep hand in neutral position. Padded, 2" blue pile material laminated to foam shoulder and body strap. Fits left or right. 5/p...
... Shoulder Immobilizer with Contoured ... Navy cotton sling with foam-padded ... body straps. Quick-release closure buckles. ... 35 covered abduction wedge to ...
... Combining the therapeutic benefits of controlled ... hemarthrosis, swelling, and pain. The anatomically designed ... treatment.,The Shoulder Cryo/Cuff can be ordered with ... to larger chest circumferences.,All Cryo/Cuffs can be ...
Medicine Products: